0
No hay productos en el carro de la compra
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Casa > Glycoprotein D (HSV-2)

Glycoprotein D (HSV-2)

Brief Information

Name:Envelope glycoprotein D
Target Synonym:
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 2 Clinical

Product Inquiry

* We couldn't find what you're looking for. You can let us help by filling the form below. Our tech team will get back to you shortly.
* This form is only used to collect product demand consultation. All the information will be kept strictly confidential.
Product inquiry collection form
*
*
*
*
*
*
*
*
*
ACRO Quality

Synonym Name

gD

Background

Herpesvirus infections are widely spread throughout the world population. Herpes simplex virus (HSV) belongs to the α-herpesvirus subfamily. There are two main types of HSV, HSV-1 and HSV-2, which infect humans. HSV-2 mainly causes genital lesions, whereas HSV-1 is involved in both oral and genital infections. Glycoprotein D (gD) is a structural component of the herpes simplex virus type 1 (HSV-1) envelope which is essential for virus entry and fusion with host cells. gD plays an important role by binding to the host receptors such as herpes virus entry mediator (HVEM) and nectin-1, a member of the immunoglobulin (Ig)-like cell adhesion molecules.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
UB-621 UB-621 Phase 2 Clinical United Biopharma Inc Herpes Simplex; Herpes Genitalis Details
UB-621 UB-621 Phase 2 Clinical United Biopharma Inc Herpes Simplex; Herpes Genitalis Details

This web search service is supported by Google Inc.

totop
Email
Correo electrónico
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland

Dejar un mensaje